Introduction {#S1}
============

To date, cancer treatment included chemotherapy, radiotherapy, and surgery. According to multiple side effects, low efficacy, and high risk of relapse accompanied by prior treatment methods, novel treatment strategies with higher efficacy and lower side effects have been introduced ([@B1]). Immunotherapy, boosting patient's own immune system to fight diseases, has recently attracted much attention as a new treatment method for cancer. Adoptive cell therapy (ACT) is among the latest progressions in immunotherapy ([@B2]--[@B4]). One encouraging method of the ACT is the adoptive transfer of genetically engineered T cells to express chimeric antigen receptor (CAR). Eshar recommended the initial theory of CAR in 1989, which proposed to equip T cell with CAR in order to redirect it against a specific tumor antigen ([@B5]--[@B8]).

Chimeric antigen receptor is a kind of engineered T cell receptor with the ability to recognize a pre-defined target Ag and introduce it to the T cell, in order to activate its cytotoxicity against target cells. CAR T cell recognizes tumor surface antigen in an antibody-like recognition pattern which is independent of MHC ([@B9]). This enables CAR T cells to recognize an extensive range of targets including proteins, carbohydrates, and glycopeptides. After distinguishing the specific target antigen on tumor cells, CAR T cells would be able to kill them ([@B10]).

Chimeric antigen receptor is composed of four domains including extracellular domain, hinge or spacer, transmembrane (TM), and intracellular domain. The extracellular domain is typically constructed from the Single chain Variable Fragment (ScFV) part of a specific antibody which is directed against the target antigen. The Spacer/Hinge domain is usually made of IgG~1~ and influences the flexibility of extracellular domain and function of the CAR T cell. TM domain is mostly derived from CD8/CD28 and affects the expression of CAR on T cell membrane. The intracellular domain consists of CD3 signaling pathway which activates the T cell after binding to the target cell. Co-stimulatory domains such as CD28 and 4-1BB, which are applied for construction of second and third generation of CAR T cells, can improve the proliferation, cytokine production, anti-tumor potency, and persistence of the T cell by providing the secondary signaling pathway ([@B11]).

Up to now, four generations of CAR T cells have been introduced. The first generation (1G) includes ScFV as the target recognition and CD3ζ signaling chain as the intracellular domain. The second generation (2G) encompasses a co-stimulatory domain such as 4-1BB (CD137) or CD28 as the secondary signal producer in addition to properties of the first generation. Applying both co-stimulatory domains including CD28 and 4-1BB led to the construction of the third generation (3G) of CAR T cells ([@B12]). Moreover, the fourth generation (4G) also named as T cell Redirected for Universal Cytokine Killing (TRUCK T cell) or armored CAR T cell, combines the properties of the 2G with enhanced ability to be more efficient against the tumor, such as the capability of cytokine secretion. Multiple cytokines such as interleukin-15 (IL-15) ([@B13]) and IL-12 have been recruited to empower CAR T cell therapy against the cancer cells ([@B2]) (Figure [1](#F1){ref-type="fig"}).

![Structure of the four generations of chimeric antigen receptors. Created by Esmaeilzadeh et al.](fimmu-09-01717-g001){#F1}

The process of producing CAR T cells for the clinical application includes multiple steps. First, mononuclear cells are isolated from patient's peripheral blood. Then, stimulation/activation of T cells is performed *via* monoclonal antibodies (such as anti-CD28 and anti-CD3) or cytokines (such as IL-2, IL-15, and IL-17). After stimulation, the transgene encoding CAR is transfected to the T cell through viral or non-viral approaches such as retroviral and lentiviral vectors, transposon (including Sleeping Beauty and PiggyBac), and plasmid; however, most clinical trials have employed retroviral vectors for gene transfer ([@B14]). Special characteristics and limitations of each vector are addressed in Table [1](#T1){ref-type="table"}.

###### 

Characteristics and limitations of each vector utilized for chimeric antigen receptor (CAR) transgene transduction.

  Vector            Special properties                                        Limitations
  ----------------- --------------------------------------------------------- ----------------------------------------------------------------
  Gammaretroviral   Integration into the cell genome ([@B15])                 Insertional oncogenesis ([@B15])
                                                                              High expense and cost ([@B16])
                    Permanent expression of the gene ([@B16])                 Affecting active dividing cells ([@B15])
                    Availability of multiple packaging systems ([@B15])       Decrease in expression of CAR after a while ([@B16])
                                                                              Restricted cargo capability ([@B15])
                                                                              
  Lentiviral        Affecting non-dividing cells                              Missing extensive accessible vector packing systems ([@B18])
                    Improved cargo capability ([@B17])                        Diverse lot-to-lot features ([@B17])
                    Decreased chance of insertional oncogenesis ([@B18])      
                                                                              
  Transposon        Stable integration to cell genome ([@B19])                Low efficacy ([@B19])
                                                                              
  DNA plasmid       Lower cost ([@B20])                                       Reduced efficacy ([@B22])
                    Low immunogenicity ([@B21])                               Decreased genome integration ([@B22])
                    Decreased risk of insertional oncogenesis ([@B21])        Early exhaustion of T cells ([@B21])
                                                                              Limited persistence and expansion of engineered cells ([@B20])
                                                                              
  Messenger RNA     Transient expression of the transgene (1 week) ([@B23])   No integration of the transgene into the cell genome ([@B23])

After transduction, genetically modified T cells are cultured to reach the appropriate number in order to have expected efficacy. Different steps of CAR T cell production take about 2 weeks. The final step is to infuse genetically modified T cells to the patients ([@B13], [@B24], [@B25]) (Figure [2](#F2){ref-type="fig"}).

![The procedure of autologous chimeric antigen receptor (CAR) T cell production. Created by Esmaeilzadeh et al.](fimmu-09-01717-g002){#F2}

Administrating significant clinical guidelines and notifying CAR T cell therapy considerations guarantee the quality and safety of this treatment method. It is necessary to set specific and standard guidelines for the application of CAR T cells. The process of CAR T cell production can be applied both by Good Manufacturing Practices or automated manufacturing ([@B26], [@B27]).

In conclusion, CAR T cells are living drugs with special ability to persist and proliferate in patient's body. The process of CAR T cell production from preclinical steps to clinical administration raises some challenges and controversies which slow down the rate of its development. The aim of this article is to determine the obstacles and forecast the upcoming novel generations of CAR T cell engineering by investigating present data from recruiting and completed clinical trials. This may provide a new insight of CAR T cell engineering and a promising window to create smarter next generation of CAR T cells.

An Overview of Ongoing Trials and Antigen Targets {#S2}
=================================================

Up to January 2018, 241 clinical trials have been registered at [clinicaltrials.gov](clinicaltrials.gov). 171 clinical trials are ongoing, most of which focus on hematological malignancies. There are many reasons for this, such as high incidence and accessible cell surface markers of hematological malignancies. Seven clinical trials are of unknown status. Most of the studies are in phase 1 or 2, although there is one study in phase 3 (NCT03027739) and one study in phase 4 (NCT02992834). The first country to start CAR T cell trials was the USA. Other countries also commenced multiple trials thereafter. 56 trials are ongoing in the USA, 104 in East Asia, 3 in Canada, 2 in Pacifica, 1 in Japan, 13 in Europe, and 1 in the Middle East (Figure [3](#F3){ref-type="fig"}).

![Geographical distribution of ongoing chimeric antigen receptor (CAR) T cell therapy clinical trials for cancer. USA and China hold most of the trials; however, other countries have also considered holding trials. Created by Esmaeilzadeh et al.](fimmu-09-01717-g003){#F3}

Most trials have focused on CD19^+^ B-cell hematologic malignancies such as acute lymphoblastic leukemia (ALL), lymphoma, and chronic lymphoblastic leukemia (CLL). The clinical outcome of patients treated with CD19 CAR T cells is promising, leading to complete or partial remission (PR) after treatment in many cases ([@B28]). Currently, 116 out of 238 trials target CD19. Following the success gained in CAR T cell therapy of hematological malignancies, many other clinical trials focus on both hematologic and solid tumors. Currently, 74 studies aim at solid tumors and at 161 hematological malignancies. Also, some clinical trials targeting other diseases have been designed. Currently, there are two trials aiming for HIV/AIDS (NCT03240328, NCT02471430) and one aims at systemic lupus erythematosus (SLE) (NCT03030976).

Most studies of hematological malignancies focus on CD19. However, other targets have also been studied such as CD22, CD20, IM19, BMCA/TACI, P-BMCA-101, CD13, and CD5. In solid tumors, targets include programmed death 1 (PD-1) \[for epidermal growth factor receptor (EGFR) family member positive advanced solid tumors\], GD2 (neuroblastoma and sarcoma), EphA2 (in glioma), AFP (hepatocellular carcinoma), ErbB2/Her2 \[in human epidermal growth factor receptor 2 (HER2) positive cancers\], MUC-1 (advanced refractory solid tumors), mesothelin ([@B29]), carcinoembryonic antigen (CEA) ([@B30]), prostate-specific membrane antigen ([@B31]), glypican 3 (hepatocellular carcinoma), interleukin-13Ra2 (IL-13Ra2), EGFR, EGFR variant III \[recurrent glioblastoma multiform (GBM)\], and VEGFR2 (metastatic melanoma) (Table [2](#T2){ref-type="table"}).

###### 

Information of ongoing clinical trials registered in [clinicaltrials.gov](clinicaltrials.gov).

  -------------------------------------------------------------------------------------------------------------------------------------------
  Target antigen                                      Disease                                     Phase    Clinical trial identifier code\*
  --------------------------------------------------- ------------------------------------------- -------- ----------------------------------
  **Clinical trials of hematological malignancies**                                                        

  CD19                                                Leukemia                                    1 or 2   NCT02975687,\
                                                                                                           NCT03097770,\
                                                                                                           NCT03208556,\
                                                                                                           NCT03016377,\
                                                                                                           NCT03263208,\
                                                                                                           NCT03064269,\
                                                                                                           NCT02924753,\
                                                                                                           NCT03142646,\
                                                                                                           NCT03391739

                                                      Lymphoma                                    1 or 2   NCT03029338,\
                                                                                                           NCT02081937,\
                                                                                                           NCT03146533,\
                                                                                                           NCT02842138,\
                                                                                                           NCT03208556,\
                                                                                                           NCT02652910

                                                      Lymphoma and leukemia                       1 or 2   NCT02819583,\
                                                                                                           NCT03383952,\
                                                                                                           NCT03271515,\
                                                                                                           NCT03110640

                                                                                                           

  CD20                                                Leukemia and lymphoma                       1 or 2   NCT02710149

                                                                                                           

                                                      Lymphoma                                    2        NCT03277729,\
                                                                                                           NCT02965157

                                                                                                           

  CD19 and CD20                                       Leukemia and lymphoma                       1        NCT03097770,\
                                                                                                           NCT03019055

                                                      Lymphoma                                    1 or 2   NCT03207178

                                                                                                           

  CD22                                                Leukemia and lymphoma                       2        NCT02935153

                                                      Lymphoma                                    1        NCT03244306

                                                                                                           

  CD19 and CD22                                       Leukemia and lymphoma                       1 or 2   NCT03233854,\
                                                                                                           NCT03185494,\
                                                                                                           NCT03098355

                                                                                                           

  CD30                                                Lymphoma                                    1        NCT03383965,\
                                                                                                           NCT03049449

                                                                                                           

  BCMA                                                Multiple myeloma                            1 or 2   NCT03287804,\
                                                                                                           NCT03288493,\
                                                                                                           NCT03070327,\
                                                                                                           NCT03338972,\
                                                                                                           NCT03322735,\
                                                                                                           NCT03380039

                                                                                                           

  CD123                                               AML                                         1        NCT03114670

                                                      BPDCN                                       1        NCT03203369

                                                                                                           

  CD33                                                Leukemia and lymphoma                       1        NCT03126864

                                                                                                           

  Ig k                                                Lymphoma                                    1        NCT00881920

                                                      Myeloma                                              

                                                      Leukemia                                             

                                                                                                           

  ROR1                                                Breast                                      1        NCT02706392

                                                      Lung                                                 

                                                      Acute lymphoblastic leukemia                         

                                                      Chronic lymphoblastic leukemia                       

                                                      Lymphoma                                             

                                                                                                           

  **Clinical trial of solid tumors**                                                                       

                                                                                                           

  EGFR                                                Sarcoma                                     1        NCT00902044

                                                      Glioblastoma                                1        NCT02442297

                                                      Glioblastoma multiform (GBM)                1        NCT02844062

                                                      Recurrent GBM                               1        NCT03283631

                                                      Recurrent brain tumors                               

                                                      EGFR-positive colorectal cancer             1 or 2   NCT03152435

                                                      Advanced solid tumor                        1 or 2   NCT03182816

                                                      Advanced solid tumor                        1 or 2   NCT02873390

                                                                                                           

  EGFRvIII                                            Glioblastoma                                1        NCT02664363

                                                      GBM                                         1        NCT02844062

                                                      Malignant glioma                            1 or 2   NCT01454596

                                                      Brain cancer                                         

                                                      Pancreatic cancer                           1        NCT03267173

                                                                                                           

  HER2                                                HER2 positive cancers                       1 or 2   NCT02713984

                                                      Glioblastoma                                1        NCT02442297

                                                      Sarcoma                                     1        NCT00902044

                                                                                                           

  Mesothelin                                          Advanced solid tumor                        1 or 2   NCT03182803

                                                      Mesothelin positive tumors                  1        NCT02930993

                                                      Advanced solid tumor                        1 or 2   NCT03030001

                                                      Pancreatic cancer                           1 or 2   NCT01583686

                                                      Cervical cancer                                      

                                                      Ovarian cancer                                       

                                                      Mesothelioma                                         

                                                      Lung cancer                                          

                                                      Cervical cancer                             1 or 2   NCT03356795

                                                      Pancreatic cancer                           1        NCT03323944

                                                      Malignant pleural disease                   1        NCT02414269

                                                      Breast cancer                                        

                                                      Lung cancer                                          

                                                      Mesothelioma                                         

                                                      Pancreatic cancer                           1        NCT02706782

                                                      Breast cancer                               1        NCT02792114

                                                      Hepatocellular                              1 or 2   NCT02959151

                                                      Pancreatic cancer metastatic                         

                                                      Colorectal cancer metastatic                         

                                                                                                           

  PSMA                                                Cervical cancer                             1 or 2   NCT03356795

                                                      Urothelial bladder carcinoma                1 or 2   NCT03185468

                                                      Bladder cancer                                       

                                                      Prostate cancer                             1        NCT03089203

                                                                                                           

  CD70                                                Pancreatic cancer                           1 or 2   NCT02830724

                                                      Breast cancer                                        

                                                      Ovarian cancer                                       

                                                      Renal cell cancer                                    

                                                      Melanoma                                             

                                                                                                           

  MUC1                                                Lung cancer                                 1        NCT03198052

                                                      Non-small cell lung cancer                  1 or 2   NCT02587689

                                                      Triple-negative invasive breast carcinoma            

                                                      Hepatocellular carcinoma                             

                                                      Pancreatic carcinoma                                 

                                                      Advanced solid tumor                        1 or 2   NCT03179007

                                                      Gastric carcinoma                           1 or 2   NCT02617134

                                                      Colorectal carcinoma                                 

                                                      Malignant glioma of brain                            

                                                      Lung cancer                                 1 or 2   NCT03356808

                                                      Cervical cancer                             1 or 2   NCT03356795

                                                      Sarcoma                                     1 or 2   NCT03356782

                                                      Osteoid sarcoma                                      

                                                      Ewing sarcoma                                        

                                                      Pancreatic cancer                           1        NCT03267173

                                                                                                           

  GD2                                                 Neuroblastoma                               1 or 2   NCT03373097

                                                      Neuroblastoma                               1 or 2   NCT02765243

                                                      Cervical cancer                             1 or 2   NCT03356795

                                                      Relapsed or refractory neuroblastoma        1        NCT02761915

                                                                                                           

  CEA                                                 Colorectal cancer                           1        NCT02349724

                                                      Breast cancer                                        

                                                      Lung cancer                                          

                                                      Pancreatic cancer                                    

                                                      Gastric cancer                                       

                                                                                                           

  GPC3                                                Lung squamous cell carcinoma                1        NCT02876978

                                                      Hepatocellular carcinoma                    1        NCT03198546

                                                      Squamous cell lung cancer                            

                                                      Hepatocellular carcinoma                    --       NCT03146234

                                                      Hepatocellular carcinoma                    1 or 2   NCT03130712

                                                      Hepatocellular carcinoma                    1 or 2   NCT02715362

                                                                                                           

  MET                                                 Malignant melanoma                          1        NCT03060356

                                                      Breast cancer                                        

                                                                                                           

  PD-L1                                               Non-small cell lung cancer                  1        NCT03060343

                                                      Advanced lung cancer                        1        NCT03330834

                                                      Lung cancer                                 1        NCT03198052
  -------------------------------------------------------------------------------------------------------------------------------------------

*BMCA, B-cell maturation antigen; Ig, immunoglobin; ROR1, receptor tyrosine kinase-like orphan receptor; MUC, mucin; EGFRvIII, EGFR variant III; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; GPC3, glypican 3; CEA, carcinoembryonic antigen; PSMA, prostate-specific membrane antigen; PD-L1, programmed death-ligand 1; PD-1, programmed death-1*.

*\*Data of ongoing clinical trials are confirmed by [clinicaltrials.gov](clinicaltrials.gov)*.

Clinical Advantages of CAR T Cell Therapy in Malignancies {#S3}
=========================================================

Advantages of CAR T Cell Therapy in Hematological Malignancies {#S3-1}
--------------------------------------------------------------

CD19 is a specific marker of B-cell lineage, not being expressed on other cell lines, and thus could be an attractive target for engineering T cells against several B-cell hematological malignancies ([@B32]). Considerable clinical responses of relapsed/refractory (R/R) B-ALL treatment with CD19 CAR T cells have been reported. There are several groups informing complete remission (CR) rate up to 90% in CD19 CAR T cell therapy of R/R B-ALL patients ([@B33]--[@B35]). Also, some studies have reported the efficacy of CD19 CAR T cells in lymphoma patients, which led to more than 40% response in diffuse large B cell lymphoma and more than 70% in indolent lymphoma ([@B36]). In a survey documented in 2015, CD19 CAR T cell therapy in multiple myeloma led to the eradication of the disease after 12 months ([@B37], [@B38]). Also, targeting five patients of CD138^+^ multiple myeloma led to stable disease state in four of them ([@B39]). In CLL, around 50% of patients treated with CAR T cells experienced remission for more than 5 years of infusion ([@B40]). Another clinical trial enrolled four CLL patients in which three of them exhibited CR and one resulted in PR ([@B6]).

CD33 is a surface antigen presented by more than 80% of the AML malignant cells, but also is expressed on normal myeloid progenitor cell lines. Preclinical promising data proposed CD33 CARs to be employed for clinical use. In a relapsed and refractory acute myeloid leukemia patient, CAR T cells reported to induce a short time benefit related to the high levels of cytokines in the patient's blood; however, substantial adverse effects including fever and fluctuations in the pancytopenia were later reported ([@B41]).

As mentioned above, CD19 is the most targeted antigen in hematological malignancies; however, sometimes B cells lose the expression of CD19 on their surface. This would lead to the resistance to CD19 CAR T therapy. In a phase 1 study in 2018, B-ALL patients who were resistant to CD19 CAR T cell therapy were treated with CD22 CAR T cells. This study demonstrated a biologic dose-dependent anti-tumor activity of CARs in an antigen density-dependent manner ([@B42]). CD20 can be targeted in different diseases especially lymphoma. In 2016, a phase 2 trial administrated anti-CD20 CAR T cells for refractory/relapsed CD20^+^ B-cell non-Hodgkin's lymphoma patients. From 11 patients, 3 patients exhibited partial responses and 6 experienced CRs. Also, no substantial toxicities were reported. This study also revealed that the underlying reason for the differences between disease progression and the patient may be related to the levels of CAR gene ([@B43]). Clinical advantage of engineering CAR T cells against other antigens of hematological malignancies is still being investigated.

Exploitation of CAR T Cells Against Solid Tumors {#S3-2}
------------------------------------------------

In contrast with impressive outcomes achieved using CAR T cells against hematological malignancies, results in solid tumors seem to be less favorable. This which may be related to the immunosuppressive microenvironment of solid tumors, reduced potency of CAR T cells in order for trafficking to tumor environment, the absence of appropriate tumor-associated antigens (TAAs) and the risk of side effects especially on-target off-tumor ([@B44]). Hostile tumor microenvironment contributes to decrease the optimum efficacy of CAR T cells *via* multiple mechanisms such as the activity of fibroblasts and extracellular matrix, soluble factors/cytokines (such as TGFβ), and immunosuppressive immune cells including T-regs and myeloid-derived suppressor cells (MDSCs) ([@B45]). Thus, multiple novel approaches need to be designed to improve the efficacy of these cells.

In order to bring the benefit of CAR T cells to the clinic, some *in vitro* studies were performed which demonstrated their efficacy on multiple solid cancer cell lines. In this article, we focus on the clinical administration of CARs, especially on patients. Multiple solid malignancies have been targeted by CAR T cells. One important step is the recognition of appropriate tumor antigen that is highly and specifically expressed on tumor cells. Epidermal growth factor receptor (EGFR) is expressed by more than 50% of non-small cell lung carcinoma cells and thus may a good candidate. In 2016, Feng et al. ([@B46]) evaluated the efficacy and safety of EGFR-CAR T cells in 11 patients. The CAR T cells were infused in multiple doses. This study reported two patients to experience partial response and five patients experienced stable disease.

Human epidermal growth factor receptor 2 is a cell surface antigen presented on several cancers including breast, ovarian, GBM, and medulloblastoma. There are some studies reporting the preclinical efficacy of CAR T cells in HER2^+^ GBM, ovarian breast, osteosarcoma, and medulloblastoma of orthotopic xenogeneic models ([@B47]--[@B51]). A phase 1 clinical trial assessed the benefit of HER2-specific CAR T cells for HER2^+^ sarcoma. The infused T cells reported persisting at least 6 weeks in seven patients of nine who were evaluable. Also, in three patients, the tumor was reported to remove with more than 9% necrosis. This study exhibited considerable tumor eradication and anti-tumor activity with no evident toxicities in patients ([@B52]). There are several other ongoing trials targeting multiple TAAs in different solid tumors such as mesothelin, IL-13Rα2, and CEA.

An important part of the limited efficacy of CAR T cells against solid tumors is related to the immunosuppressive tumor microenvironment. This hurdle can be overcome by administration of the transgene encoding IL-12 by the T cells. In 2015, a phase 1 study targeted six recurrent MUC16^ecto+^ ovarian carcinoma patients with armored IL-12 secreting CAR T cells. The selection of an appropriate TAA along with the secretion of IL-12 by T cells led to the enhanced persistence of the CAR T cells. Also, the expression of the IL-12 appropriately modulated the tumor microenvironment and increased the cytotoxicity of the cells ([@B53], [@B54]).

Several trials have targeted different solid cancers and variable results have been achieved; however, more modifications and engineering approaches are required to improve the advantage of CAR T cell therapy in solid tumors.

Side Effect and Toxicity {#S4}
========================

Although excellent results have been achieved in CAR T cell therapy trials, they can also be accompanied by some adverse effects. CAR T cell infusion may even cause some life-threatening toxicities ([@B44]). Some of these side effects are discussed here.

Cytokine Release Syndrome (CRS) {#S4-1}
-------------------------------

Cytokine release syndrome is the most prevalent toxicity observed after infusion of engineered T cells. Its occurrence is related to the intense activation of the infused T cells which activate other immune cells; altogether, producing the extended amount of cytokines resulting in a cytokine storm ([@B55]). CRS is so dangerous since it can cause fever, nausea, fatigue, myalgia, vascular leakage, hypotension, and multiple organ failures. Even death can be accompanied by CRS following infusion of CAR T cells ([@B56]). Multiple organs and systems including cardiovascular, pulmonary, renal, hepatic, musculoskeletal, and hematologic systems may also be involved in CRS. The predisposition factors for CRS are high tumor burden as well as the high dosage of infused CAR T cells. Also, stronger propagation and activation of T cells increases the risk of CRS ([@B57]). Recently, some serum biomarkers have been introduced as predictive biomarkers for CRS such as high levels of CRP (over 20), IL-6, and IFNγ ([@B58]).

On-Target Off-Tumor Toxicity {#S4-2}
----------------------------

On-target off-tumor toxicity occurs when T cells lose the ability to distinguish normal cells from tumor cells. TAAs are the most antigens employed for the production of CAR T cells and are expressed on both tumor and normal cells. Attacking normal cells expressing TAA leads to the destruction of them named as on-target off-tumor toxicity ([@B59]).

The most common form of on-target off-tumor toxicity is the destruction of B-cells which leads to B-cell aplasia. This is commonly observed in CD19 CAR T cell therapies ([@B60]). Since HER antigen is expressed by cardiac and pulmonary epithelial cells, HER2 CAR T cells applied for breast cancer can exhibit cardiopulmonary toxicity ([@B48]). Based on a case report in 2010, ERBB2 CAR T cell therapy for colorectal cancer led to the death of the patient because of pulmonary toxicity ([@B56]).

In order to reduce the range of this toxicity, more specific antigens such as tumor-specific antigens (TSAs), only expressed on tumor cells are preferred for CAR T cell designing.

Neurotoxicity {#S4-3}
-------------

Neurotoxicity has been observed in some trials, which can be a result of T-mediated inflammation, elevated cytokine levels in CNS and cerebral edema; however, the exact reason has not been known yet. Symptoms of neurotoxicity of CAR T cells include aphasia, confusion, delirium, word finding difficulty, myoclonus, and seizure ([@B35], [@B59]). Hu et al. reported an R/R ALL female who experienced neurological symptoms because of cerebral CRS, 6 h and 3 days after transfusion of the autologous CAR T cells. The patient was then treated with methylprednisone until day 14 which diminished patient's symptoms completely ([@B61]). Although most centers have reported neurotoxicity to be self-limited with no long-term neurologic deficits, some death cases have been reported related to the neurotoxicity caused by cerebral edema ([@B43]). At present, there are no standard clinical interventions for the management of the neurotoxicity, but systemic corticosteroids may be employed in case of severe side effects. Also, dexamethasone may be chosen due to its heavy penetration into the CNS ([@B62]).

Anaphylaxis {#S4-4}
-----------

Anaphylaxis is a kind of immediate toxicity related to the immunogenicity caused by murine antibody derived ScFV. Humanizing components of the CAR protein may reduce the chance of anaphylaxis, which has been discussed in further sections of this article ([@B51]). Since anaphylaxis is lethal, instant treatment of this life-threatening toxicity is necessary for the patients ([@B59], [@B63]).

Tumor Lysis Syndrome (TLS) {#S4-5}
--------------------------

Tumor lysis syndrome is also one of the toxicities correlated with sudden tumor cell death and is defined by increased lactate dehydrogenase, uric acid, and potassium levels. TLS may also result in acute kidney injury. Decreasing the size of the tumor before infusion, patient intravenous hydration, and Rasburicase treatment may be helpful to reduce the severity of TLS ([@B59]).

Insertional Oncogenesis {#S4-6}
-----------------------

Insertional oncogenesis is related to the transfer of a retroviral or lentiviral transgene to the T cells. This may be accompanied by a higher risk of malignancy induction in the target cell. The probability of oncogenesis followed by transduction seems to be low; however, more precautions and monitoring strategies will be required in future clinical trials ([@B59], [@B64]--[@B66]).

New Generations of CAR T Cells {#S5}
==============================

Four generations of CAR T cells have been produced yet; however, more modifications and developments are still in process to enhance their clinical advantage and efficacy.

Developing CAR T Cells With Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated 9 (Cas9) {#S5-1}
-------------------------------------------------------------------------------------------------------------------------

Clustered regularly interspaced short palindromic repeats/Cas9 is a novel gene manipulation technology system with a great potential for biologic genome editing processes. Administration of CRISPR/Cas9 as a novel technology for genome editing could help to design more effective therapeutic agents ([@B67]). Recently, application of CRISPR/Cas9 in combination with cancer immunotherapy has been introduced to construct the next generation of CAR T cells. Rupp et al. employed Cas9 ribonucleoprotein (Cas9 RNP) as the gene manipulation method *via* lentiviral transfer in order to produce CD19 CAR T cells insufficient of PD-1. PD-1 is a member of immune checkpoint inhibitor family. The expression of the ligand for PD-1, named PD-L1, on tumor cells can reduce the anti-tumor function of T cells and decrease their optimal activation. Disrupting the gene responsible for the expression of the PD-1 in T cells, *Pdcd1*, by CRISPR/Cas9, leads to the absence of PD-1 cell surface. This modification inhibits the anti-immune checkpoint inhibitory function of the tumor cells and has shown to increase the demolition of the PD-L1^+^ xenograft *in vivo* tumor model ([@B68]).

These data demonstrate that genome editing using CRISPR/Cas9 system may be employed to produce next generation of modified CAR T cells by genome editing of more immune checkpoints, surface antigens, and secretory enzymes, and cytokines to enhance the clinical therapeutic effects.

Designing New Targets {#S5-2}
---------------------

Although multiple approaches have been utilized to improve the anti-tumor potency of CAR T cells, selection of an optimal target antigen for the production of CAR would pave the road to produce a new generation of CAR T cells. ScFV CARs have illustrated impressive results in CAR T cell therapy for both hematological and solid malignancies; however, off-target toxicity, low specificity, and immunogenicity still remain as challenges ([@B69], [@B70]). Designing human origin ScFV-based CARs such as M28z CAR, a new CAR containing m912, led to the initiation of a clinical trial targeting mesothelioma, lung, and breast cancer (NCT02414269). Thus, humanizing the origin of ScFV can reduce the immunogenicity of CAR design.

Targeting intracellular antigens such as Wilms Tumor 1 (WT1) in cancer could provide a new road to target antigen selection ([@B71]). Rafiq et al. engineered a T-cell receptor-mimic CAR to target the intracellular oncoprotein named as WT1, which is also expressed on the cell surface through HLA-A\*02:01. These engineered WT1-28z specific CAR T cells destroyed and lysed HLA-A\*02:01, WT1^+^ tumor cells in an *in vivo* mice model ([@B71]).

Single chain Variable Fragment antibody formats with lower side effects, improved affinity, and specificity will make utilization of CARs more favorable for CAR T cell therapy. Novel antibody pieces such as single domain VH, VHH, mini, dia, and triabody have recently been introduced ([@B72], [@B73]). An example is the GPA7-28z redirected TCR-like CAR-engineered against melanoma. The ScFV domain was obtained from Lamma-derived VHH part of the antibody against melanoma cells. GPA7-28z engineered T cells possessed enhanced cytotoxic characteristics when administrated both *in vitro*, against human melanoma cells, and *in vivo*, against xenograft model ([@B74]).

Cancer stem cells (CSCs) are present in most cancers and are responsible for relapse and resistance to therapy. These cells can be distinguished from other cancer cells by specific surface antigens such as CD34, 44, 90, 133, and EpCAM ([@B75]). Targeting CSC target antigens as CAR T cell targets may provide a potential opportunity to enhance the clinical response by eliminating them. EpCAM^+^ prostate CSCs can be an appropriate target for EpCAM-specific CAR T cells since they have an important role in tumor proliferation and progression. In a study in 2015, EpCAM-redirected CAR T cells were employed against EpCAM^+^ prostate cancer in both *in vitro* and *in vivo* models. EpCAM-specific CAR T cells exhibited substantial anti-tumor toxicity against prostate metastatic tumor cells ([@B76], [@B77]).

Also, one of the major challenges that limit the function of CARs against solid tumors is the heterogeneity of tumor antigens. It is recently demonstrated that tumor cells express cancer-specific cell surface antigens that are caused by post-translational alterations of the antigens. Mostly, O-glycosylation of the antigens leads to the expression of these cancer-specific targets named as glycan-antigens. Anti-Glycan CAR T cells are the novel approach employed for the construction of the CARs that are highly specifically redirected against special tumor surface antigens. Different antibody classes, such as high-affinity O-glycopeptide antibodies, may be employed for the construction of glycan-CARs. Using glycan targets for designing CARs can emerge as a powerful tool for precisely targeting solid tumor cells ([@B78]).

The fast-growing wave of CAR T cell therapy needs the application of new unique target antigen strategies to engineering the next generations, which would lead to better clinical outcomes and fewer side effects.

Modification of TRUCK T Cells {#S5-3}
-----------------------------

TRUCK T cells or fourth generation of CAR T cells encompass the particular capability of delivering a transgenic material (payload) to the tumor site. To achieve this, T cells are engineered with a nuclear factor of activated T cell (NFAT), which is responsible for the expression of the transgenic product (such as cytokines). IL-12 is the most studied cytokine secreted by the transgene part of the CAR T cells. Production of pro-inflammatory cytokine (such as IL-12) by CAR T cells can activate both innate and adaptive immune system which leads to a robust anti-tumor immune activity. Also, IL-12 can inhibit the immune suppressor activity of myeloid-derived suppressor cells as well as regulatory T cells. CAR T cells secreting IL-12 possess enhanced anti-tumor function and improved therapeutic effect, especially when administered against solid tumors ([@B79]).

Although TRUCK T cells have shown impressive results in clinical trials, controlling the titer of the cytokine secretion must be considered. This is due to the possible toxicities in case of severe cytokine production related to the elevated amount of IFNγ. Uncontrolled secretion of IL-12 would lead to severe side effects damaging lung, liver, and bone marrow. The solution to this problem is to adjust the strength of the promoter or to administrate the NFAT to engineer promoters ([@B80]). In order to benefit this technique, two ongoing phase 1/2 clinical trials by National Institutes of Health Clinical Center have engineered TCR T cells or TILs, with the ability of cytokine secretion (IL-12), to target NY-ESO-1^+^ solid tumors (NCT01457131, NCT01236573). However, new methods that help to regulate the secretion of cytokines by TRUCK T cells, such as regulating the gene responsible for expression of the cytokine using 1miRNAs or siRNAs, are required. Also, equipping TRUCK T cells with the ability to secrete enzymes (such as heparanase) that ameliorate their infiltration to the tumor stroma can increase the number of infiltrated CAR T cells to the solid tumor site and thus can increase the anti-tumor efficacy of these cells.

In a study in 2016, the genome of the allogeneic universal CAR T cells was edited with electroporated CRISPR/Cas9 to render them resistant to PD-1 inhibition *via* editing its gene on T cells. These manipulated universal T cells decreased alloreactivity and increased the anti-tumor potential of CAR T cells ([@B81]).

Altogether, application of novel genome editing methods and strategies along with improved safety approaches may help to modify TRUCKs in through more effective outcome.

Building Smarter CAR T Cells to Increase Therapeutic Efficacy and Reduce Adverse Effects Especially in Solid Tumors {#S6}
===================================================================================================================

Adoptive cell therapy, especially CAR T cell therapy, is a combination of immune, gene, and cell therapy ([@B82], [@B83]). Engineering smarter CAR T cells improve the strength, quality, safety, efficacy, and anti-tumor function of the genetically engineered cells. Administration of CAR T cells for their anti-tumor benefit is accompanied by some adverse effects, as well. Some of the novel generations of CAR T cells are addressed in **Figure [4](#F4){ref-type="fig"}**.

![Novel modified chimeric antigen receptor (CAR) designs. Created by Esmaeilzadeh et al.](fimmu-09-01717-g004){#F4}

One method to improve the safety and manipulate the function of genetically engineered T cells is to control them by adding "switches." This strategy makes it possible to induce death or inactivate the T cells by adding an exogenous component (off-switch). The example of off-switch is the administration of Herpes Simplex Virus thymidine kinase (HSV-TK) or inducible caspase-9 (iCasp-9) as self-destruction genes, which could be activated by injection of ganciclovir and FK506 binding protein, respectively. This approach makes it possible to control the activity of CAR T cells and even to finish their activity in case of substantial toxicity. Activation of HSV-TK ([@B84]) and iCasp-9 ([@B85]) would induce the apoptosis of the T cell and cessation of its activity in order to decrease its side effects. As an example, Gargett and Brown engineered the third generation of GD-2-redirected CAR T cells with iCasp-9 against melanoma tumor cells ([@B85]).

"On-switch" CAR T cell is another approach in which an exogenous molecule can induce the activation of engineered T cells ([@B86]). On-switch has some advantages than the off-switch method; e.g., on-switch T cells are not necessarily destroyed in the absence of the exogenous component, as well as being safer than off-switch method. However, frequent administration of the activating molecule may lead to resistance of the patient to therapy ([@B87]).

Lim et al. described another targeting system based on synthetic NOTCH receptors, responsible for sensing/response behaviors, which are expressed only when it is linked to a tissue-specific ligand ([@B88]).

Inhibitory CAR (iCAR) is a new method which can be administrated to inhibit CAR T cells in case of severe toxicities. The T cell surface domain includes a receptor for PD-1 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), as normal immune checkpoint inhibitor molecules. Receptors of these immune checkpoints are expressed on T cells. Blocking these checkpoints would lead to the inactivation of the immune cell. Thus, it was proposed to inactivate CAR T cells by infusion of PD-1 or CTLA-4 in case of severe toxicities ([@B89], [@B90]).

Also, T cells can be engineered to express the CAR transiently (self-limiting CARs). Self-limiting CARs are automatically inactivated and destructed after the transient expression of CAR is over. When the functional period of CAR is over, T cells will return to their normal function in the tissue. In order for transient expression of CAR, transposon vectors are employed as gene transduction strategies ([@B91]).

Engineering T cells marked with monoclonal antibody (mAb) as cell surface antigen could launch the anti-tumor function of the cell, just in case, it is linked to the tumor cells expressing the antigen. Two examples of this strategy include the application of CD34/CD20 ([@B92]) and EGFR ([@B93]) on CAR T cells which can be eliminated by rituximab (anti-CD20 mAb) and cetuximab (anti-EGFR mAb) in case of severe toxicities. Philip et al. ([@B92]) engineered highly sensitive CD37 and CD20 antigens and administrated rituximab for selective elimination of the genetically transformed cells.

Tandem CAR (TanCAR) is another method of genetically engineering T cells in order to reduce the off-tumor toxicity. TanCAR contains two different kinds of ScFVs and is activated only if both antigens are introduced to the T cell. HER2^+^/CD19 and HER2^+/^IL-13Rα2 are two examples of TanCARs which have been studied on glioblastoma tumor expressing both antigens ([@B94], [@B95]). TanCARs can high specifically exhibit anti-tumor toxicity against tumor cells since both antigens must be present on the tumor cell surface. This specificity would increase the safety of TanCARs than conventional CARs that were only specific against one cell surface antigen.

In order to increase the precision of CAR T cells to target only cancer cells in the patient, it was proposed to concurrently engineer CAR specific against two tumor antigen named as dual CARs. Dual CARs are composed of two CARs, containing both primary signaling (CD3ζ) and secondary signaling (co-stimulatory) domains. Accumulating data suggest that simultaneous targeting of two tumor antigens can enhance the accuracy of tumor cell distinguish and empower the anti-tumor activity of CAR T cells. Also, since two tumor antigens are targeted by dual CARs, the risk of on-target, off-tumor toxicity is also reduced. In 2013, a dual mesothelin-FRaCAR coexpressing both signal 1 (anti-Meso ScFV-CD3z) and signal 2 (anti-FRa ScFV-CD28) was engineered. In this study, CAR T cells exhibited enhanced cytokine secretion only against tumor cells that expressed both antigens simultaneously, but not against cells that contained one of the antigens. These CAR T cells also involved increased *in vivo* persistence and anti-tumor activity ([@B96]). In another study, breast cancer cells were treated with HER2-mucin 1 (MUC1) CAR T cells which exhibited enhanced complementary signaling along with increased precise cytotoxicity against breast cancer cells expressing both antigens ([@B97]).

Tandem CARs and DualCARs are similar in terms of their mechanism since they both target two antigens on tumor cells; however, their mechanism of target recognition is distinct. Also, both of these strategies have reported reducing antigen escape, which is a major cause of resistance to therapy in cancer. This leads to the enhanced anti-tumor activity of CAR T cells against cancer ([@B98]).

Immunosuppressor agents infused before CD19 CAR T therapy along with B cell aplasia followed by injection of CD19 CAR T cells can lead to the invasive fungal infection (IFI), especially by *Aspergillus* and *Candida*, in patients. To solve this problem, it was proposed to engineer dual CD19-Dectin-1 CAR targeting both malignant B cells and fungal hyphae. This approach has reported to successfully inhibit the IFI after CAR-19 therapy for leukemia and lymphoma patients ([@B99]).

Decision-making CAR T cells, smart T cells activated only in a special condition, have recently been designed. These CAR T cells are engineered in a way that they are activated in the patient's body only if special environment such as hypoxia is prepared. Since hypoxia is a special characteristic of the tumor microenvironment, oxygen-sensitized CAR T cells were designed. These CAR T cells initiate their anti-tumor function only in hypoxic condition. As normal cells do not typically experience hypoxia, this prevents CAR T cells to be activated in the microenvironment of the normal cells and can thus decrease the officious side effects. Hypoxia-inducible factor (HIF) is a molecule produced in hypoxic tissues and is overexpressed by cancer cells. To engineer self-decision-making CARs, the ScFV domain was derived from an anti-HIF antibody. This enabled CAR T cells to traffic to the tumor site with a high specificity and not haring other normal tissues at the same time ([@B100]). This study paved the way to engineering CAR T cells with the potential for designing novel tumor-specific CAR T cells.

One important obstacle that inhibits the appropriate function of the CAR T cells is the limited homing of the CAR T cells to the tumor microenvironment. One solution is to modify CAR T cells in a way that they target tumor vessels. VEGF is overexpressed by tumor cells and increases the angiogenesis of the tumor leading to the production of vessels. In order to improve the homing of the CAR T cells to the tumor site, VEGFR targeted TRUCK T cells with the capability of IL-12 secretion have been introduced to aim the blood vessels of the tumor and have shown increased immigration of the cells to the tumor site ([@B101], [@B102]). Also, another approach to enhance CAR T cell delivery to the solid tumor site is to modify CAR T cells using echistatin which can strongly bind to αvβ3, a marker that is expressed by tumor vessel endothelial cells. This approach has been studied previously and promising results have been achieved ([@B103]), but more considerations need to be applied in further clinical trials.

One strategy to reduce the side effects caused by CAR T cells is to convert the progression and activation of CAR T cells dependent on specific adaptor molecules. It is recently proposed to modify antibodies (e.g., CD19 and CD22) produced for CAR production with fluorescein isothiocyanate (FITC). This strategy provides the feasibility of controlling the precise function and geometry of FITC-CAR T cells. Introducing the receptors of FITC to T cells would increase the potential anti-tumor activity and improve the trafficking of the CAR T cells to the tumor site and ([@B104]). Such targeting strategies may develop the anti-tumor potency, trafficking, and specificity of the CAR T cells.

Combinatorial immunotherapeutic approaches incorporate an immune checkpoint blockade with engineering T cells. one of the most important and effective immune checkpoint inhibitor molecules that hinders the function of the CAR T cells in tumor microenvironment is the program death that PD-1 negative CAR is designed to remain in the PD-L1 positive solid tumor microenvironment without limitation, which ameliorates the anti-tumor efficacy of CAR T cells ([@B105]).

Understanding the specific properties of the solid tumor microenvironment have provided new opportunities for modifying CAR T cells. One of the important characteristics of the solid tumor is the specific metabolism of the solid tumor which is distinct from the metabolism of the normal cells. Solid tumor metabolism leads to the production of molecules and proteins that promote its progression and angiogenesis. One important factor is the extracellular adenosine which is produced from ATP by CD73 and CD39. Adenosine promotes the angiogenesis, metastasis, and progression of the tumor cells and thus has been introduced as a promising target. Some studies have attempted to inhibit the function of adenosine either by inhibiting its receptor named as adenosine 2A receptor or its producer, CD73. These data can be as templates for designing CAR T cells that inhibit the adenosine function in clinical trials ([@B106]).

Indolamine-2,3 dioxygenase (IDO) is another tumor-associated molecule which is the catalyst for the degradation of the tryptophan, an amino acid that is necessary for the survival of T cells. High levels of IDO are produced by tumor cells and MDSCs. Inhibiting the function of IDO, *via* IDO-inhibitors, could increase the function of CAR-redirected cell therapy in clinical trials ([@B89]). Also, tumor microenvironment has known to contain high levels of anti-oxidant agents including H~2~O~2~, which can disturb the function of CAR T cells. In order to decrease the effect of H~2~O~2~ in the tumor, scientists added the ability of catalase production to the CAR T cells (CAT-CAR). Catalase producing CAR T cells were reported to possess increased resistance against the oxidative stress. Also, they were accompanied by enhanced anti-tumor activity in the tumor site ([@B107]).

Since tumor stroma is one of the major obstacles that limit the penetration of the CAR T cells to the tumor site, scientists thought to engineer CAR T cells against the fibroblast-associated protein (FAP), which is highly expressed by tumor-associated fibroblasts. These CAR T cells are named FAP-CARs. FAP-CAR T cells have been reported to increase the anti-tumor response and the survival of the xenograft models ([@B108], [@B109]), which has introduced it as an appropriate strategy for clinical trials (NCT01722149).

One of the limiting factors of the tumor is the immunosuppressive cytokine network including TGF-β, IL-1, and IL-4, which are present in the tumor site. Since these anti-immune soluble factors can hamper the function of T cells, inhibiting these anti-immune pathways could increase the efficacy of CAR T cells. Based on these data, Mohammed et al. engineered CAR T cells against prostate stem cell antigen (PSCA-CAR) which were modified by fusion of the IL-4 exodomain to the IL-7 endodomain (4/7 ICR CAR). This novel modification of CAR T cell was named as 4/7 ICR CAR-PSCA and was reported to increase the anti-tumor cytotoxicity of CAR T cells in the tumor site ([@B110]).

Although favorable efforts have been made to design smarter CAR T cells, more genetic and structural modifications of CAR may be helpful to increase the applicability and clinical outcomes of this adoptive immunotherapy approach. Since solid tumor microenvironment is the limiting factor for optimal function of CAR T cell therapy, it seems that further efforts must focus to overcome the microenvironment immunosuppressor effects.

Clinical Considerations {#S7}
=======================

Combining CAR T cell therapy with other immunotherapy methods such as immune checkpoint inhibitors, cytotoxic agents, and hematopoietic stem cell transplant (HSCT) may lead to better clinical outcomes. Concomitant treatment of cancer using CAR T cells and checkpoint inhibitors that block PD-1, the ligand for PD-1 (PD-L1), and CTLA-4 has exhibited great efficiency in preclinical stages. It was demonstrated that blockage of PD-1 may reinforce the CAR-T cell therapeutic effects ([@B111], [@B112]).

Integration of chemotherapy as lymphodepletion regimen with CART cells may improve its clinical efficacy. This may be related to multiple mechanisms such as downregulation of regulatory T cells, depletion of interfering leukocytes and decrease in tumor burden after chemotherapy. Also, diminution of CAR T cell toxicities especially CRS has been seen in the usage of this method ([@B113]). The most applied agent as lymphodepletion regimen is cyclophosphamide; although, other chemotherapy regimens such as fludarabine, doxorubicin, and platinum-based chemotherapeutics can also be administered.

Also, allogeneic HSCT can improve the therapeutic potential of CAR T cell therapy. The optimum time for the infusion of CAR T cells is 55--200 days following HSCT ([@B114], [@B115]).

The best outcomes may be achieved by combining cell therapy methods with routine and standard treatment strategies ([@B115]).

CAR T Cell Dosage Modification {#S7-1}
------------------------------

In order to improve the efficacy and lower the toxicities induced by CAR T cells, injection dose is divided into multiple doses. To obtain expected outcomes, the dosage of CAR T cells must reach 7.5 × 10^7^ to 3.4 × 10^8^. Of note, the number of T cells containing CAR determines the entire number of infused cells. Different centers utilize multiple infusion courses and the optimal time lapse between infusions still remains controversial ([@B116]).

Infusion Method {#S7-2}
---------------

After all processes of CAR T cell manufacturing, the whole volume of the product may raise to 5 l. This volume cannot be infused to the patient in one step, thus it must be divided into volumes that could be infusible ([@B117]). Different methods have been examined in order for injection of CAR T cells to the patients. Brown et al. carried out a study which exhibited 77% decrease in intracranial and spinal Glioblastoma mass lesions in intraventricular infusion method in 33 weeks. The most prevalent approach is an intravenous injection. Other infusion methods include catheter infusion, hepatic artery infusion, ultrasound-guided intratumoral injection, intraperitoneal, and intrapleural ([@B118]).

Product Quality Control {#S7-3}
-----------------------

The quality of the CAR T cell product affects its clinical efficacy which depends on the quality of donor cells, additional reagents and substances, manufacturing protocols, and CAR T cell production environment. Quality control tests are currently documented for CAR T cell clinical trials. These tests aim to focus on safety (e.g., Gram stain, mycoplasma, and endotoxin), identity (% CAR T cells), sterility, purity (e.g., %CD3^+^ T cells and %CAR T cells), bacterial and fungal contamination ([@B119]). Also, titer, stability, and function of the viral vector should be measured and attended ([@B87]). It is noteworthy to attend the name and label of the product before infusion, especially in autologous CAR T cell products.

Are All Patients Candidate for CAR T Cell Therapy? {#S7-4}
--------------------------------------------------

Patients with special characteristics would be appropriate for CAR T cell infusion. Some of these conditions include cancer must have a unique target antigen (e.g., CD19), the patient must have appropriate performance condition and enough tolerance to possible side effects. Also, the patient must have an adequate number of T cells to be isolated and engineered. Patients who have experienced severe autoimmune disease do not qualify to participate; this is related to the probability of disease exacerbation during the infusion period time or the immunosuppressive drugs they receive. It is recommended that if a patient's cancer is in control or remission phase, allogeneic HSCT is preferred than CAR T cell therapy ([@B120]).

Toxicity Control and Follow-Up {#S7-5}
------------------------------

Since CAR T cell infusion is accompanied by hazardous toxicities which may endanger patients, hospital admission and observation during infusion period seems to be necessary. In case of B-cell aplasia following CD19 CAR T cell infusion, intravenous immunoglobulin injection must be considered. To prevent and control severe CRS, anti-IL-6, vasopressor support, and hydration strategies are pivotal. If a patient experiences neutropenic fever, supportive care and standard considerations must be performed based on guidelines ([@B120]).

Also, to realize the effectiveness of treatment in patients, follow-up is required to measure the rate of stable disease, PR and CR conditions. However, the follow up period has been variable between different studies according to their limitations ([@B116]).

Concluding Remarks {#S8}
==================

Impressive outcomes have been achieved with CAR T cell therapy especially in patients with CD19^+^ malignancies. This has led to the development of several studies applying CAR T cells in numerous cancers. Although USA and China are responsible for most clinical trials, CAR T cell therapy is growing rapidly all over the world.

Two products including Kymriah by Novartis and Yescarta by Kite Pharma have recently gained FDA approval. Kymriah can be administrated for B-ALL and lymphoma patients and Yescarta for large B-cell lymphoma ([@B121]). Improving CAR T cell production protocols, target selection, and clinical considerations may lead to the advent of multiple genetically engineered drugs for different cancers, especially solid tumors.

Results related to clinical trials of different centers are substantially variable which is related to the tumor type, CAR T cell phenotype, production, and application strategies selected. Using the information released by these trials could be beneficial to create new strategies in order to ameliorate targeting, anti-tumor function, tissue penetration, and perseverance of CAR T cells in further studies.

Future Directions {#S9}
=================

Adoptive cell therapy using CAR T therapy have been applied for many years but still, some challenges have remained which hinder its optimized function; so, there is a requirement to enhance the efficacy of CAR T cells against tumor cells.

Cell Type Selection {#S9-1}
-------------------

To improve the existence, proliferation and expansion time of CAR T cells in patients, particular subtypes of less differentiated T cells such as αβ T cells are preferred ([@B101]). Moreover, selection of central memory T cells or CD4^+^/CD8^+^ T cells as initiating cell population is considered to decrease the cell variability of the product ([@B46], [@B87], [@B122]). Blaeschke et al. administrated central and stem memory T cells to engineer 4-1BB CAR T cells against CD19^+^ ALL. This study exhibited that using robust memory composition of T cells for designing CAR T cells can increase the expansion of these cells up to 100-fold. These CAR T cells also showed higher efficacy ([@B123]).

NK cells may also be chosen as a target cell to be transduced with the CAR transgene. Chen et al. engineered CD3CAR NK92 cells to target the T cell malignancies which led to the control and suppression of Jurkat tumor cells ([@B124]).

Combination Therapy {#S9-2}
-------------------

It is recently documented that CAR T cell therapy combined with immune checkpoint inhibition could improve its anti-tumor effect ([@B125]). Also, CAR T cell therapy accompanied by chemotherapy and HSCT may lead to prolonged survival and a better outcome for patients ([@B126]). Altogether, a combination of new treatment strategies with CAR T cell therapy could lead to enhanced anti-tumor efficacy.

New Target Identification {#S9-3}
-------------------------

To enhance the specificity of CAR T cell against tumor cells and reduce the adverse effects, TSAs must be selected. With the identification of new unique targets both for hematological and solid malignancies, improved anti-tumor efficacy and better outcomes are expected.

From Hematologic Malignancies to Solid Tumors {#S9-4}
---------------------------------------------

Application of CAR T cells has represented favorable results with durable immunity especially in hematological malignancies; however, CAR T cell therapy in solid tumors is still in its early stages of the experiment. Multiple trials have aimed to explore the benefit of CAR T cell therapy in solid tumors, but the results have not been impressive. This problem has been attributed to the immunosuppressive microenvironment of the solid tumors that inhibits the activation and function of the CAR T. Specific characteristics of solid tumor microenvironment include obstacles in T cell trafficking, anti-immune function (several immunosuppressive cytokines and immune cells), and fibrotic tissue of solid tumors (presence of fibroblasts). Also, due to the stromal structure of solid tumors, CAR T cells show limited infiltration to the solid tissue ([@B2], [@B127]). A comparison of obstacles of CAR T cell therapy in solid tumors and hematological malignancies and possible solutions have been presented in Table [3](#T3){ref-type="table"}.

###### 

A comparison of obstacles and feasible solutions of applying chimeric antigen receptor (CAR) T cells in solid tumors and hematological malignancies.

  Challenges in solid tumors                                                                                                  Feasible solutions                                                                                                                                        Challenges in hematological malignancies                Feasible solutions
  --------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  Trafficking to the solid tumor site                                                                                         Local infusion of CAR T cells ([@B29])                                                                                                                    Antigen escape                                          Targeting two antigens (such as CD19/CD20) *via* dual CARs ([@B129])
                                                                                                                              Pro-inflammatory chemokine production by CAR T cells ([@B79])                                                                                                                                                     
                                                                                                                              Engineering tumor site-specific CAR T cells (e.g., hypoxia-inducible factor sensitized and epidermal growth factor receptor sensitized CARs) ([@B100])                                                            
                                                                                                                              Engineering CAR T cells with chemokine receptors (CXCR2, CCR4) ([@B128])                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                
  The immunosuppressive microenvironment of the malignant tumor: cytokines, immune inhibitory checkpoints, and immune cells   Reduction and inhibition of regulatory T cells by lymphodepletion ([@B113])                                                                               B-cell aplasia and multiple infections after infusion   Intravenous immunoglobulin injection ([@B60])
                                                                                                                              Employment of exogenous interleukin (IL)-2, IL-7, and IL-12 for enhancing CAR T cell efficacy ([@B119])                                                                                                           Dual CD19-Dectin-1 CAR T cells ([@B99])
                                                                                                                              Programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 blockade by monoclonal antibody ([@B89], [@B125])                                                                                       
                                                                                                                              Administering clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 for engineering PD-1-knockout CAR T cells ([@B68])                                                           
                                                                                                                              Designing other inhibitory-molecule knockout CAR T cells                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                
  Target antigen heterogenicity and specificity                                                                               Dual CARs targeting two antigens simultaneously ([@B97])                                                                                                  Reduced number of CAR T cells in patient's blood        Multiple infusions of CAR T product ([@B130])
                                                                                                                              Identifying more tumor-specific antigens proprietary for solid tumor                                                                                                                                              
                                                                                                                              Administrating glycan-CARs to increase the tumor-specificity of CAR ([@B78])                                                                                                                                      
                                                                                                                              Indication of specific CARs for patients with particular antigen expression profile                                                                                                                               
                                                                                                                              Identifying new tumor-unique antigens                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                
  Controlling side effects                                                                                                    Engineering smarter CAR T cells \[e.g., inhibitory CARs (iCARs), "on-off switch" CARs, split CARs\] ([@B90])                                              Severe acute side effects                               iCARs ([@B90])
                                                                                                                              Predicting cytokine release syndrome (CRS) *via* specific biomarkers (e.g., IL6, CRP, and IFNγ) ([@B59])                                                                                                          Predicting CRS *via* specific biomarkers (e.g., IL6, CRP, and IFNγ) ([@B59])
                                                                                                                              Administration of anti-IL6 (Tocilizumab) and hydration methods in case of severe toxicity ([@B59])                                                                                                                Administration of anti-IL6 (Tocilizumab) and hydration methods in case of severe toxicity ([@B59])
                                                                                                                              Transient expression of CAR ([@B76])                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                
  Limited *in vivo* persistence                                                                                               Selecting appropriate T cell subgroups                                                                                                                                                                            
                                                                                                                              Simultaneous infusion of T cell stimulating cytokines (IL-12, IL-15, and IL-18) ([@B59])                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                
  Penetration to the solid tumor stroma                                                                                       Anti-fibroblast-associated protein-CAR T cells ([@B131])                                                                                                                                                          
                                                                                                                              Heparanase expressing CAR T cells (HPSE-CAR) ([@B132])                                                                                                                                                            

Other Diseases {#S9-5}
--------------

The extreme potential of CAR T cell therapy has turned it into a promising treatment method against other non-cancerous diseases such as HIV/AIDS, SLE, sepsis, and fungal infections. CAR T cell therapy provides a promising era of ACT for even more diseases.

Preconditioning Regimen {#S9-6}
-----------------------

The preconditioning regimen used for chemotherapy expands the duration of CAR T cells' function. As a result, some changes in chemotherapy regimen may be useful. Recently, cyclophosphamide has been introduced as a selective chemotherapy regimen. Further researches would determine the best preconditioning cytotoxic agents.

Modulation of Toxicity {#S9-7}
----------------------

As a powerful cytotoxic treatment method, CAR T cell therapy is followed by some side effects. Although several approaches such as anti-IL-6 (Tocilizumab) have been introduced for CRS diminution, more interventions are required to decrease side effects without disturbing the function of CAR T cells. Also, novel strategies such as employment of suicide genes, dual CARs, transient mRNA transfection, iCARs, and switch CAR T cells can be administrated to terminate the function CAR T cells in case of serious toxicity.

Autologous or Allogeneic T Cells? {#S9-8}
---------------------------------

Most studies have utilized autologous T cells to produce CAR T cells; however, some challenges such as higher expense, lower quantity, and quality still exist ([@B67]). Although allogeneic CAR T cells have represented impressive outcomes in relapsed hematological malignancies, there is a chance of GVHD after infusion. Accumulating data declare allogeneic CAR T cells to be safe and effective after allogeneic HSCT. Also, GVHD prophylaxis *via* cyclophosphamide has shown to decrease the risk of GVHD ([@B115], [@B133], [@B134]). Ghosh et al. reported allogeneic CAR T cells to exhibit graft-versus-lymphoma effect accompanied by decreased GVHD ([@B135]). Also, administration of allogeneic T cells to produce CAR T cells may vanquish exhaustion and senescence of T cells especially in CLL patients ([@B136]).

In conclusion, CAR T cell therapy has been introduced as a novel therapeutic strategy with impressive outcomes, especially in hematological malignancies. Further studies are required to determine whether developing new generations of CAR T cell therapy can shift efforts from cancer treatment to cancer cure!
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